Parkinson’s disease is a chronic, degenerative neurological disorder affecting one in 100 people over the age of 60 and more than five million people worldwide. Currently there is no objective test or biomarker for Parkinson’s disease, and the rate of misdiagnosis can be relatively high.

Clarifi PD aims to identify biomarkers in saliva that are highly accurate in identifying early onset Parkinson’s disease

In cooperation with SUNY Upstate Medical University, Quadrant Biosciences is in the research and development phase of identifying biomarkers in saliva that are highly accurate in characterizing early onset Parkinson’s disease.  Through an evaluation of human and oral microbial transcripts, next-generation sequencing technology allows us to examine the molecular content of saliva (including human and environmental factors) implicated in the onset of Parkinson’s Disease. Merging this with patient data allows for the development of a highly accurate, non-invasive diagnostic aid for PD.

Published Research

• The oral microbiome of early stage Parkinson’s disease and its relationship with functional measures of motor and non-motor function, PLOS One, June 2019

Interested in participating in our research? Click the link below to learn more.